Neuroblastoma

disorder

SNOMED 432328008CUI C0027819

Overview

Source: MedlinePlus.gov, National Library of Medicine. Not a substitute for medical advice.

Treatments & Interventions

Doxorubicin hydrochloride

substance

Doxorubicin

substance

Vincristine

substance

Isotretinoin

substance

Melphalan

substance

Etoposide

substance

Cisplatin

substance

Dactinomycin

substance

Cyclophosphamide

substance

Vincristine sulphate

substance

Dacarbazine

substance

Daunorubicin hydrochloride liposome

substance

Melphalan hydrochloride

substance

Etoposide phosphate

substance

Dinutuximab

substance

Cyclophosphamide monohydrate

substance

Doxorubicin hydrochloride pegylated liposome

substance

Naxitamab

substance

Cyclophosphamide anhydrous

substance

Clinical Trials

Total Trials

Recruiting

With Results

Recent Trials

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT01109394Recruiting6,035 enrolled

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

NCT01005654Recruiting2,415 enrolled

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

NCT02559778Phase 2Recruiting500 enrolled

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296Phase 3Recruiting478 enrolled

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119Phase 1/PHASE2Recruiting147 enrolled

View all 11 trials on ClinicalTrials.gov

Research Evidence

Peer-reviewed studies linked via MeSH term "Neuroblastoma" from the MEDLINE/PubMed database.

Sort:

Induction Regimens in High-Risk Neuroblastoma: Systematic Review of Response Rates and Toxicities.

[object Object], [object Object], [object Object] et al. · Cancer Med · 2025

PMID: 41276891Meta-AnalysisFull text (PMC)

Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed/Refractory High-Risk Neuroblastoma.

[object Object], [object Object], [object Object] · Target Oncol · 2025

PMID: 40459700Meta-AnalysisFull text (PMC)

Late toxicity after upper abdominal radiotherapy in pediatric Wilms tumor and neuroblastoma survivors. A systematic review on behalf of SIOPEN and SIOP-RTSG.

[object Object], [object Object], [object Object] et al. · Radiother Oncol · 2025

PMID: 40441488Meta-Analysis

Risk factors of neuroblastoma: a systematic review and meta-analysis.

[object Object], [object Object], [object Object] et al. · Front Public Health · 2025

PMID: 40636854Meta-AnalysisFull text (PMC)

A Comparison of Commonly Utilized Diagnostic Biopsy Techniques for Pediatric Patients With Cancer: A Systematic Review by the APSA Cancer Committee.

[object Object], [object Object], [object Object] et al. · J Pediatr Surg · 2025

PMID: 39317569Meta-Analysis

Latin American Consensus on the Use of Anti-GD2 Monoclonal Antibody Therapy in Patients With High-Risk Neuroblastoma.

[object Object], [object Object], [object Object] et al. · JCO Glob Oncol · 2025

PMID: 41435217Meta-Analysis

I-mIBG therapy in relapsed/refractory neuroblastoma: A weapon from the future past.

[object Object], [object Object], [object Object] et al. · Crit Rev Oncol Hematol · 2025

PMID: 39732302Meta-Analysis

Tackling ALT-positive neuroblastoma: is it time to redefine risk classification systems? A systematic review with IPD meta-analysis.

[object Object], [object Object], [object Object] et al. · Neoplasia · 2025

PMID: 39733691Meta-AnalysisFull text (PMC)

The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.

[object Object], [object Object], [object Object] et al. · Eur J Nucl Med Mol Imaging · 2024

PMID: 37962616Meta-AnalysisFull text (PMC)

Image-guided core-needle or surgical biopsy for neuroblastoma diagnosis in children: A systematic review and meta-analysis from the International Society of Pediatric Surgical Oncology (IPSO).

[object Object], [object Object], [object Object] et al. · Pediatr Blood Cancer · 2024

PMID: 38015091Meta-Analysis

Search all PubMed articles for Neuroblastoma

Research data from MEDLINE/PubMed

Signs & Symptoms

Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.

Cancer of early nerve cells

Very frequent (80-99%)HP:0003006

Elevated urinary catecholamines

Very frequent (80-99%)HP:0011976

Tumour of the nervous system

Very frequent (80-99%)HP:0004375

Abdominal mass

Frequent (30-79%)HP:0031500

Belly bloating

Frequent (30-79%)HP:0003270

Chronic diarrhoea

Frequent (30-79%)HP:0002028

Decreased haemoglobin

Frequent (30-79%)HP:0001903

Elevated circulating catecholamine level

Frequent (30-79%)HP:0003334

Low platelet count

Frequent (30-79%)HP:0001873

Pyrexia

Frequent (30-79%)HP:0001945

Swollen lymph nodes

Frequent (30-79%)HP:0002716

Tiredness

Frequent (30-79%)HP:0012378

Weight loss

Frequent (30-79%)HP:0001824

Anemic pallor

Occasional (5-29%)HP:0001017

Antalgic gait

Occasional (5-29%)HP:0031955

Bleeding tendency

Occasional (5-29%)HP:0001892

Blood coagulation disorder

Occasional (5-29%)HP:0001928

Bone pain

Occasional (5-29%)HP:0002653

Elevated urinary homovanillic acid

Occasional (5-29%)HP:0011977

Elevated urinary vanillylmandelic acid

Occasional (5-29%)HP:0011978

Horner syndrome

Occasional (5-29%)HP:0002277

Increased lactate dehydrogenase level

Occasional (5-29%)HP:0025435

Increased serum ferritin level

Occasional (5-29%)HP:0003281

Irritable mood

Occasional (5-29%)HP:0000737

Laboured breathing

Occasional (5-29%)HP:0002098

Multiple, subcutaneous nodules

Occasional (5-29%)HP:0001482

Pathologic fracture

Occasional (5-29%)HP:0002756

Prominent globes

Occasional (5-29%)HP:0000520

Spinal cord compression

Occasional (5-29%)HP:0002176

Ataxia

Very rare (1-4%)HP:0001251

Related Conditions

Paraspinal neuroblastoma(child)

Thoracic neuroblastoma(child)

Pelvic neuroblastoma(child)

Adrenal neuroblastoma(child)

Metastatic neuroblastoma(child)

Neuroblastoma of central nervous system(child)

Primary neuroblastoma(child)

Malignant tumour(parent)

NEN - neuroendocrine neoplasm(parent)

Quick Facts

SNOMED CT: 432328008
UMLS CUI: C0027819
Fully Specified Name: Neuroblastoma (disorder)
Specialists: 0
Diagnostic Biomarkers: 0
HPO Phenotypes: 30
Known Treatments: 19
Clinical Trials: 11

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.